BETA: Please send your feedback!
Celldex Therapeutics
CLDX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2021
—
About
Biotechnology
Founded 1983
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
website
Headquarters
Executives
| Name | Title | Gender |
| Thomas Andrew Davis, MD | Chief Medical Officer & Executive Vice President | Male |
| Avery W. Catlin, MBA, CPA | CFO, Secretary, Treasurer & Senior Vice President | Male |
| Larry Ellberger | Chairman | Male |
| Anthony S. Marucci, MBA | President, Chief Executive Officer & Director | Male |
| Tibor Keler, PhD | Chief Scientific Officer & Executive VP | Male |
| Sarah Boylan Cavanaugh | VP-Investor Relations & Corporate Communications | Female |
| Theresa M. LaVallee, PhD | Senior VP-Regulatory & Precision Medicine | Female |
Mindful Investing Summary
Celldex Therapeutics - Competitors and Related Companies
How Celldex Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Celldex Therapeutics
CLDX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2021
—
Agenus
AGEN:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2021
—
Emergent BioSolutions
EBS:NYS
Biotechnology
—
MID cap
(—)
—
since start of 2021
—
Northwest Biotherapeutics
NWBO:OTC
Biotechnology
—
MICRO cap
(—)
—
since start of 2021
—
Seattle Genetics
SGEN:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2021
—
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—